6-methyl-3,4-dihydroquinoxalin-2(1H)-one | 854583-97-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 6-methyl-3,4-dihydroquinoxalin-2(1H)-one
• 英文别名: 6-methyl-3,4-dihydro-1H-quinoxalin-2-one
• CAS: 854583-97-4
• 化学式: C₉H₁₀N₂O
• 分子量: 162.191
• InChiKey: FLHYWKXOCOAFLT-UHFFFAOYSA-N

物化性质

• 沸点：
  366.0±42.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-methyl-3,4-dihydroquinoxalin-2(1H)-one 在 potassium tert-butylate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 20.5h， 生成 tert-butyl 7-methyl-5-[(3S,5R)-3,4,5-trimethylpiperazine-1-carbonyl]-4H-imidazo[1,5-a]quinoxaline-3-carboxylate
  参考文献：
  名称：

  Piperazine Imidazo[1,5-a]quinoxaline Ureas as High-Affinity GABA_A Ligands of Dual Functionality

  摘要：

  A series of imidazo[1,5-alpha]quinoxaline piperazine ureas appended with a tert-butyl ester side chain at the 3-position was developed. Analogues within this series have high affinity for the gamma-aminobutyric acid A (GABA(A))/benzodiazepine receptor complex with efficacies ranging from inverse agonists to full agonists. Many analogues were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Uniquely, a number of these analogues were found to have a bell-shaped dose-response profile in the alpha(1)beta(2)gamma(2) subtype as determined by whole cell patch-clamp technique, where in vitro efficacy was found to decrease with increasing drug concentration. Many of the compounds from this series were effective in antagonizing metrazole-induced seizures, consistent with anticonvulsant and possibly anxiolytic activity. Additionally, several analogues were also effective in lowering cGMP levels (to control values) after applied stress, also consistent with anxiolytic-like properties. The most effective compounds in these screens were also active in animal models of anxiety such as the Vogel and Geller assays. The use of the piperazine substituent allowed for excellent drug levels and a long duration of action in the central nervous system for many of the quinoxalines, as determined by ex vivo assay. Pharmacokinetic analysis of several compounds indicated excellent oral bioavailability and a reasonable half-life in rats. From this series emerged two partial agonists (55, 91) which had good activity in anxiolytic models, acceptable pharmacokinetics, and minimal benzodiazepine-type side effects.

  DOI：

  10.1021/jm9801307
• 作为产物：
  描述：

  Ethyl 2-(5-methyl-2-nitroanilino)acetate 在 盐酸 、 tin 作用下， 以 乙醇 为溶剂， 反应 1.5h， 生成 6-methyl-3,4-dihydroquinoxalin-2(1H)-one
  参考文献：
  名称：

  Piperazinylquinoxalines with central serotoninmimetic activity

  摘要：

  Regioselective syntheses of substituted 2-chloroquinoxalines and derived 2-(1-piperazinyl)quinoxalines are described. Selectivity in regards to serotonin reuptake blocking and serotoninmimetic activities of the piperazinylquinoxalines is reported. In general, introduction of a 6-substituent into the piperazinylquinoxaline enhanced serotonin reuptake blocking activity and diminished serotoninmimetic activity. Unsubstituted and 3-hydroxypiperazinylquinoxalines had primarily serotoninmimetic activity.

  DOI：

  10.1021/jm00133a019

文献信息

• [EN] COMPOUNDS, DEVICES, AND USES THEREOF<br/>[FR] COMPOSÉS, DISPOSITIFS ET UTILISATIONS ASSOCIÉES
  申请人：SIGILON THERAPEUTICS INC

  公开号：WO2018067615A1

  公开（公告）日：2018-04-12

  The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.

  本发明提供化合物，例如，具有式（I）的化合物和药用可接受的盐、溶剂化合物、水合物、互变异构体、立体异构体、同位素标记衍生物及其组合物。还提供包括相同化合物的可植入元件（例如，设备和材料），以及使用方法，例如，用于治疗或预防疾病、紊乱或状况。
• TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
  申请人：Hutchinson John Howard

  公开号：US20070173508A1

  公开（公告）日：2007-07-26

  Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物抑制5-脂氧合酶（5-LO）的活性。本文还描述了使用这种5-LO抑制剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖或介导白三烯的状况、疾病或紊乱。
• [EN] HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'ANTAGONISTES DE L'ADÉNOSINE
  申请人：NUVATION BIO INC

  公开号：WO2020150677A1

  公开（公告）日：2020-07-23

  Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了氨基吡嗪化合物作为腺苷受体的调节剂。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。
• A Combination of Visible-Light Organophotoredox Catalysis and Asymmetric Organocatalysis for the Enantioselective Mannich Reaction of Dihydroquinoxalinones with Ketones
  作者：Jaume Rostoll-Berenguer、Gonzalo Blay、M. Carmen Muñoz、José R. Pedro、Carlos Vila

  DOI：10.1021/acs.orglett.9b02157

  日期：2019.8.2

  An enantioselective photooxidative Mannich reaction of dihydroquinoxalinones with ketones by the merger of organophotoredox and asymmetric organocatalysis is described. This protocol features very mild reaction conditions using simple and cheap catalysts (Eosin Y and (S)-Proline) for the synthesis of chiral quinoxaline derivatives with good to high yields (up to 94%) and excellent enantioselectivities

  描述了通过有机光氧化还原和不对称有机催化的结合，二氢喹喔啉酮与酮的对映选择性光氧化曼尼希反应。该方案具有非常温和的反应条件，使用简单且廉价的催化剂（曙红Y和（S）-脯氨酸）合成手性喹喔啉衍生物，具有良好至高产率（高达94％）和出色的对映选择性（高达99％ee） 。
• [EN] SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF<br/>[FR] INHIBITION PAR DES PETITES MOLÉCULES DU FACTEUR DE TRANSCRIPTION SALL4 ET SES UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2019070943A1

  公开（公告）日：2019-04-11

  Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.

  本文提供了一些干扰SALL4功能的化合物。同时还描述了这些化合物的药物组合物和医疗用途。